FilingReader Intelligence

Fosun Pharma announces leadership changes, board restructuring, new investments

April 29, 2025 at 05:14 PM UTCBy FilingReader AI

Shanghai Fosun Pharmaceutical (Group) Co. (HKEX: 2196) has announced a series of significant changes to its leadership, board structure, and investment strategy. Effective April 29, 2025, Mr. Wu Yifang and Mr. Wang Kexin resigned from their respective positions as Chairman and Co-Chairman. Mr. Chen Yuqing has been elected as the new Chairman, with Ms. Guan Xiaohui as Co-Chairman, and Mr. Wen Deyong as Vice Chairman. The Board also appointed Mr. Chen Yuqing as an Authorised Representative and will re-designate Mr. Wu Yifang from executive to non-executive director and Mr. Chen Yuqing from non-executive to executive director. In addition, Mr. Xu Xiaoliang, Ms. Li Ling, and Mr. Tang Guliang retire from the board, while Mr. Yang Yucheng and Mr. Chen Penghui are proposed as new independent non-executive directors. The company intends to amend the Articles of Association to enable one employee director.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Shanghai Fosun Pharmaceutical (Group) Co publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →